|
?:abstract
|
-
The aim of the article was to discuss the current challenges for management of immune thrombocytopenia (ITP) during COVID-19 pandemic, based on the practical experience and interim expert recommendations suggested by the hematology societies Based on some criteria, three scenarios could be expected for any hospitalized patient with COVID-19 and thrombocytopenia: known ITP (chronic), who develops COVID-19, new onset ITP (acute) and COVID-19 at the same time and for the first time, and thrombocytopenia in patients with COVID-19 unrelated to ITP For evaluation of all these three categories, a review of previous records is crucial, as it might save a lot of time and prevent from ordering unnecessary investigation for the evaluation of thrombocytopenia while taking care of a patient with COVID-19 Also, it is important to note that the timing of thrombocytopenia in patients with COVID-19 can be remarkably variable and patients with COVID-19 can rarely present in the form of acute ITP or relapse As the universal bearing of COVID-19 grows daily, the International ITP Coalition remains devoted to the health and safety of the patients with ITP The Platelet Disorder Support Association, American Society of Hematology (ASH), British Society of Hematology (BSH) and other international hematology societies are working relentlessly to ensure that constant updates and developments made readily available in the form of interim guidance to the treating physicians and hematologists worldwide
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}